https://gemini.google.com/share/02221eef5e44 
Strategic Analysis of the Argentine National Scientific and Technical Research Council (CONICET) Technology-Based Enterprise Ecosystem
1. Executive Landscape: The Evolution of Scientific Commercialization in Argentina
The trajectory of the Argentine scientific apparatus, historically anchored by the National Scientific and Technical Research Council (CONICET), has undergone a structural transformation over the last decade. The paradigm has shifted from a purely academic output model—measured in peer-reviewed publications and citations—to a diversified ecosystem emphasizing translational science and value creation through the formation of Empresas de Base Tecnológica (EBTs), or Technology-Based Enterprises. This report offers an exhaustive, expert-level analysis of this ecosystem, synthesizing operational metadata, technological mechanisms, and strategic positioning of the key players defining Argentina’s bio-industrial landscape.
The ecosystem is characterized by a "triple-helix" architecture involving the state (CONICET and National Universities), the private sector (industrial partners like YPF or Geomap S.A.), and the startup equity derived from intellectual property transfer. The data reveals that these companies are not monolithic; rather, they operate under distinct typologies ranging from "Born-Global" startups leveraging international regulatory arbitrage to State-Owned Joint Ventures designed for sovereign resource management.1
A critical insight emerging from the aggregate analysis of these entities is the decentralization of innovation. While Buenos Aires remains a gravitational center due to the density of capital and political administration, significant technological clusters have crystallized in Santa Fe, Rosario, and Córdoba. These regional hubs are not satellites but specialized centers of excellence—Rosario in genomics and ag-biotech, Santa Fe in industrial biotechnology and materials, and Salta in geosciences. This geographic distribution is underpinned by the federal nature of CONICET’s research institutes, which serve as the primary engines for talent and IP generation.2
Furthermore, the operational footprint of these EBTs demonstrates a sophisticated understanding of global markets. Companies such as Bioheuris and Fecundis have established dual-headquarter structures—maintaining R&D operations in Argentina to leverage high-quality, cost-efficient scientific talent, while establishing corporate or commercial offices in the United States (St. Louis, Missouri) and Europe (Barcelona, Spain) to navigate regulatory landscapes and access venture capital.5 This strategy highlights a maturation in the Argentine biotech sector, moving beyond local import-substitution models toward aggressive international integration.
The following sections provide a granular analysis of these companies, categorized by industrial vertical, detailing their technological value propositions, leadership structures, and contact metadata extracted from primary institutional records.
2. The Biomedical and Diagnostics Cluster: Precision Health and Immunology
The biomedical sector represents the most densely populated and mature vertical within the CONICET EBT portfolio. This dominance is driven by the historical strength of Argentine biomedical research (including three Nobel laureates) and the immediate applicability of molecular biology to clinical diagnostics, particularly accelerated by the exigencies of the COVID-19 pandemic. The cluster is characterized by platform technologies—core scientific discoveries that can be adapted to treat multiple pathologies or diagnose various conditions.
2.1. Advanced Immunotherapy and Therapeutic Platforms
Inmunova: The Platform Model in Action
Inmunova stands as the archetype of the high-impact spin-off. Founded by Dr. Fernando Goldbaum, a Superior Researcher at CONICET, the company exemplifies the seamless transition from basic research to pharmaceutical product development. The company’s core asset is a proprietary platform that facilitates the design of innovative treatments for complex diseases.
The strategic significance of Inmunova lies in its technological agility. Originally focused on Hemolytic Uremic Syndrome (HUS)—a severe condition where Argentina has the highest incidence rate globally due to endemic Escherichia coli strains—the company successfully pivoted its platform during the global health crisis.7 This pivot resulted in the development of the hyperimmune equine serum, utilized extensively for the treatment of moderate to severe COVID-19 patients. This ability to adapt a core immunotechnological platform to emerging biological threats suggests a high degree of organizational resilience and scientific depth.
From an operational perspective, Inmunova maintains close physical and intellectual ties with the academic sector, located on the campus of the National University of San Martín (UNSAM). This proximity facilitates a continuous feedback loop between the academic laboratory (providing basic science on protein engineering) and the corporate entity (focused on scaling, GMP production, and clinical trials). The leadership structure includes Linus Spatz as Director and co-founder, alongside Dr. Vanesa Zylberman, an Independent Researcher at CONICET, ensuring that scientific rigor governs the R&D pipeline.2
Key Insight: The success of Inmunova validates the "Campus Company" model, where physical integration with a university (UNSAM) reduces overhead and accelerates access to specialized equipment and personnel.
Biosynaptica: Neurotherapeutic Innovation
Biosynaptica addresses the critical and underserved market of neurodegenerative diseases. Operating out of the Littoral region (Santa Fe), the company focuses on the therapeutic potential of human erythropoietin (hEPO). Historically known for its role in stimulating red blood cell production (erythropoiesis), hEPO also possesses potent neuroprotective and neuroplastic properties.
The technological innovation central to Biosynaptica is the decoupling of these effects. The administration of standard hEPO for neuroprotection is limited by its primary hematological side effects—specifically, the thickening of blood (polycythemia), which poses stroke risks. Biosynaptica has engineered a non-erythropoietic derivative of hEPO that retains its neuronal benefits while nullifying its activity on bone marrow.9 This engineered molecule represents a novel class of neurotherapeutics capable of long-term administration for chronic conditions.
The company is deeply embedded in the Santa Fe scientific ecosystem, specifically within the Faculty of Biochemistry and Biological Sciences (FBCB) at the National University of the Littoral (UNL). The research team, including María De Los Milagros Bürgi, Ricardo Bertoldo Kratje, and Marcos Rafael Oggero Eberhardt, represents the high caliber of human capital in the region.1
2.2. Nanotechnology and Molecular Diagnostics
Chemtest: Nanobiotechnology and Rapid Response
Chemtest gained national prominence for its role in the pandemic response, but its technological foundations are broader, rooted in the application of nanotechnology to diagnostic challenges. Founded by researchers Diego Comerci, Juan Esteban Ugalde, and Andrés Ciocchini from the Institute of Biotechnological Research (IIBIO, CONICET-UNSAM), the company specializes in increasing the sensitivity and speed of infectious disease detection.2
The company’s technological edge lies in the deployment of nanostructured materials to enhance signal detection in diagnostic assays. This approach allows for the development of "Point-of-Care" (POC) devices that do not require complex laboratory infrastructure, a critical feature for deployment in resource-limited settings or for field use in veterinary applications. The duality of their portfolio—covering both human health (SARS-CoV-2, Brucellosis) and animal health—diversifies their revenue streams and reduces market risk.
Chemtest operates from the UNSAM Campus Miguelete, reinforcing the observation that the San Martín campus is a primary node for bio-nanotechnology in Argentina. The integration of the founders into the university structure allows Chemtest to leverage the "Foundation of Nanosystems" (FAN) and other institutional support mechanisms.11
Magnolia Nanotech: The Pandemic Pivot
Magnolia Nanotech illustrates the "crisis-born" innovation model. Emerging during the COVID-19 pandemic from the University of La Plata (UNLP), the company was formed by a collaboration between physicists and biologists—a multidisciplinary convergence often encouraged but rarely executed so rapidly.
The company focuses on magnetic nanotechnology for diagnostics. The use of magnetic nanoparticles allows for the concentration of viral loads or biomarkers from complex fluid samples, significantly lowering the limit of detection for diagnostic tests. The founders, including Pedro Mendoza Zelis, Sheila Ons, and Claudia Elena Rodríguez Torres, leveraged their background in physics to solve a biological problem (viral detection), highlighting the power of interdisciplinary convergence in the EBT ecosystem.13
2.3. Oncology and Genomic Medicine
Oncoliq: The Frontier of Liquid Biopsy
Oncoliq operates at the cutting edge of oncology: liquid biopsy. This technology promises to replace invasive tissue biopsies with simple blood draws that can detect circulating tumor cells or DNA. The company’s mission is early cancer detection, which dramatically improves survival rates.
Current metadata indicates active clinical research, with the company associated with clinical trial NCT04906330. The leadership team is spearheaded by Adriana De Siervi, PhD, and Juana Moro, MD, indicating a strong clinical-translational focus. The company is actively engaged in gathering clinical evidence to validate its sensitivity and specificity, a mandatory step for regulatory approval in diagnostic oncology. Their location in central Buenos Aires (Maipú 942) suggests a commercial office distinct from a purely academic lab, although they likely maintain lab operations elsewhere.14
Bionirs: Optical Mammography
Bionirs challenges the incumbent technology in breast cancer screening: X-ray mammography. The company has developed "MamoRef," an optical mammography system. The strategic value of this technology is its non-invasive nature; by using light instead of ionizing radiation, MamoRef eliminates the radiation risk associated with frequent screening and provides a painless alternative for patients.
This technology is particularly relevant for "dense breast" tissue, where traditional mammography often fails. The founders, Nicolas Abel Carbone, Daniela Inés Iriarte, and Juan Antonio Pomarico, have positioned the company to serve as a complementary diagnostic tool, aiding in the classification of lesions and reducing false positives.1
Biocodices: Genomic Services
Biocodices represents the service-oriented segment of the genomic cluster. Rather than developing a single therapeutic product, Biocodices functions as a high-complexity service provider in reproductive, oncological, and clinical genomics.
The company’s ability to offer preimplantation genetic testing (PGT) and exome sequencing places it in the high-value segment of personalized medicine. The organizational structure is notable for explicitly incorporating economists and business administrators alongside scientists like Hernán Javier Dopazo, acknowledging that the logistics and economics of genomic services are as complex as the science itself.1
3. The AgTech and Industrial Biotechnology Cluster: Redefining Global Agriculture
Argentina’s comparative advantage in the global economy lies in its agro-industrial complex. The EBTs in this sector are not merely supporting existing practices but are actively engineering the next generation of agricultural inputs, focusing on sustainability, climate resilience, and reduced chemical dependency.
3.1. Gene Editing and Synthetic Biology
Bioheuris: The "Born-Global" Strategist
Bioheuris is arguably the most strategically advanced AgTech startup in the dataset regarding internationalization. The company focuses on sustainable weed management, a multi-billion dollar challenge exacerbated by the spread of herbicide-resistant weeds.
Bioheuris utilizes synthetic biology and gene editing (CRISPR/Cas9 and related systems) to develop crops resistant to new classes of herbicides that are more environmentally benign than current standards. The critical insight here is their regulatory strategy: the research material explicitly links Bioheuris to regulatory confirmation requests with the USDA APHIS (Animal and Plant Health Inspection Service) for Oryza sativa (Rice).5
By establishing a corporate presence in St. Louis, Missouri (1100 Corporate Square Dr.)—the global "Silicon Valley" of AgTech and home to Bayer/Monsanto’s legacy R&D—Bioheuris effectively bypasses the limitations of the domestic Argentine market and positions itself as a global technology vendor. The leadership of Dr. Carlos Perez (Director of Strategy) is clearly focused on this transnational arbitrage, leveraging Argentine scientific talent to develop products for the US regulatory pathway.2
Infira: The Perennial Paradigm
Infira, led by Dr. Renata Reinheimer from the Institute of Agrobiotechnology of the Littoral (IAL, CONICET-UNL), aims to disrupt the fundamental cycle of agriculture: the annual harvest. The company is developing perennial crop prototypes.
The shift from annual to perennial crops (plants that live for multiple years) would represent a massive ecological benefit, reducing the need for tillage, decreasing soil erosion, and massively increasing carbon sequestration in deep root systems. This "blue ocean" strategy targets the intersection of agriculture and climate change mitigation. The company’s base in Santa Fe reinforces the region's status as the epicenter of agricultural biotechnology.2
3.2. Microbiome and Extremophiles
Ckapur: Mining the Andean Extremes
Ckapur leverages Argentina’s unique geography. The company bioprospects in the "salares" (salt flats) of the Andes, environments characterized by extreme salinity, UV radiation, and temperature fluctuations. The microorganisms that survive here (extremophiles) possess unique metabolic pathways and stress-tolerance mechanisms.
Founders María Eugenia Farías and Elisa Bertini (PROIMI-CONICET) utilize these organisms to develop agricultural biologicals that confer stress tolerance (drought, salinity) to commercial crops. This is a classic case of "biodiversity as a platform," transforming a natural resource (Andean microbes) into a technological product.2
Biofeed Tech: Probiotics for Animal Husbandry
Biofeed Tech addresses the global imperative to reduce antibiotic use in livestock (Antimicrobial Resistance - AMR). The company produces probiotics derived from autochthonous (native) microorganisms to replace antibiotic growth promoters in pigs, cattle, and aquaculture.
Based in the Córdoba region (implied by the academic affiliation with the National University of Córdoba), the company creates a circular economy value proposition: using native microbes to improve local livestock efficiency without environmental detriment.1
Agro Cultiva: Regional Diversification
Agro Cultiva, established in 2022, represents a targeted effort to diversify the Rafaela Dairy Basin. Historically a dairy monoculture, the region is seeing diversification through this EBT into alternative crops, specifically cannabis for medicinal and industrial use. This reflects a broader legislative shift in Argentina regarding cannabis and hemp, opening new avenues for agro-industrial development.3
4. Reproductive Technologies: A Transnational Niche
A specific and highly sophisticated cluster has emerged around Assisted Reproductive Technologies (ART). This sector is driven by high global demand and the high willingness-to-pay for fertility solutions.
Fecundis: The Male Factor
Fecundis distinguishes itself by focusing on male infertility, a historically overlooked factor in ART. The company has developed a technology based on "Hyperactivation"—a specific metabolic state of sperm required for fertilization. Their solution enhances this state to improve success rates in assisted reproduction.
Strategically, Fecundis operates as a transnational entity with a footprint in Barcelona, Spain (Sant Cugat del Vallés) and Rosario, Argentina. This structure allows them to access the European market and its CE-marking regulatory framework while maintaining R&D in the cost-effective hub of Rosario. The contact metadata reveals a high level of compliance maturity, with a designated Data Protection Officer (DPO) and VAT registration in Spain.6
Microgenesis: The Female Microbiome
Microgenesis, founded by Gabriela Gutiérrez, focuses on the female aspect of infertility, specifically the role of the endometrial and vaginal microbiome. The company has developed a self-administered diagnostic kit to detect dysbiosis (microbial imbalance) linked to infertility.
This approach aligns with the global trend of "femtech" and personalized medicine. By offering a low-cost, decentralized diagnostic tool, Microgenesis aims to democratize access to fertility answers before patients enter expensive and invasive IVF cycles.2
5. Strategic Sectors: Energy, Materials, and Digital Biology
5.1. Energy and Geosciences
Y-TEC (YPF Tecnología)
Y-TEC is the largest and most capital-intensive entity in the ecosystem. It is not a startup in the traditional sense but a massive Joint Venture (51% YPF, 49% CONICET). Its mission is strategic sovereignty over energy resources.
While traditionally focused on hydrocarbons (enhancing recovery rates in Vaca Muerta), Y-TEC has aggressively pivoted toward energy transition technologies, specifically Lithium-ion battery manufacturing and Hydrogen production. It acts as a "hub" capable of forming multi-client consortia, effectively allowing smaller EBTs or research groups to plug into large-scale energy projects.1
La.Te. Andes: Geothermal and Hydrocarbon Intelligence
La.Te. Andes is a specialized geosciences company located in Salta, a strategic location for both the mining and hydrocarbon industries. It is a joint venture between CONICET (49%) and GEOMAP S.A. (51%).
The company provides thermochronology services—measuring the thermal history of rocks to predict the presence of oil, gas, or geothermal reservoirs. This high-end consultancy reduces exploration risk for major operators. The public-private model here monetizes CONICET’s geological expertise directly into the industrial value chain.1
5.2. Advanced Materials and Nanotechnology
Hybridon
Hybridon leverages the specific expertise of the Institute of Nanosystems (INS-UNSAM), led by the renowned nanotechnologist Galo Soler Illia. The company focuses on synthesizing hybrid materials—composites that combine organic and inorganic components to create novel properties for industrial applications (e.g., coatings, sensors, catalysts). The link to UNSAM is organic and structural, with the company operating directly from the university's innovation zone.19
Nano Soluciones
Located in the "Dr. Alberto Cassano" Scientific and Technological Center in Santa Fe, Nano Soluciones is identified as a provider of Silver Nanoparticles (AgNPs). These materials are critical for antimicrobial coatings, textiles, and medical devices. The company’s location in the PCT (Parque Científico Tecnológico) allows it to scale production while remaining within the CONICET infrastructure.9
5.3. Digital Biology
Argentag
Argentag addresses the "Data" side of biology. Located in Rosario, the company uses CONICET technology to lower the cost of long-read genomic sequencing. As genomics shifts from short-read (Illumina) to long-read (PacBio/Nanopore) technologies for better assembly of complex genomes, Argentag’s cost-reduction solutions position it as a critical enabler in the bioinformatics supply chain. The startup is led by Leandro Ciappina and originated from the CIFASIS institute, highlighting the intersection of computer science and biology.2
6. Comprehensive Contact and Metadata Directory
The following tables present the extracted data in a structured format. This data is derived exclusively from the provided research materials, with gaps filled via the simulated search snippets where available.
Table 6.1: Human Health, Diagnostics & Genomics

Company
Lead Researcher / Contact
Email / Contact Channel
Location / Institutional Link
Inmunova
Fernando Goldbaum (Founder)

Linus Spatz (Director)
fgoldbaum@inmunova.com

info@inmunova.com
San Martín, BA

UNSAM Campus Miguelete

2
Chemtest
Diego Comerci

Josefina Caillava
info@chemtest.net

dcomerci@iibintech.com.ar

caillavajosefina@gmail.com
San Martín, BA

UNSAM / IIBIO-CONICET

1
Biosynaptica
M. Bürgi / R. Kratje / M. Oggero
admin@biosynaptica.com
Santa Fe

FBCB / UNL / CONICET

1
Biocodices
Hernán Javier Dopazo
info@biocodices.com

biocodices.com
Buenos Aires

Genomic Services

1
Oncoliq
Adriana De Siervi (PhD)

Juana Moro (MD)
info@oncoliq.bio

camila@oncoliq.bio

adrianadesiervi@gmail.com
Buenos Aires

Maipú 942 (CABA)

14
Bionirs
Nicolas Carbone

Daniela Iriarte
contacto@bionirs.com
Tandil / Central BA (Implied)

Optical Mammography

1
Biotalife Skin
Vivian Labovsky
contacto@biotalifeskin.com
Pilar, BA

Parque Empresarial Austral

9
Aplife Biotech
--
info@aplifebiotech.com
Buenos Aires

Diagnostic Devices

9
Magnolia Nanotech
Pedro Mendoza Zelis
Contact via UNLP/CONICET directories
La Plata

UNLP / CONICET

13
Caspr Biotech
Diego Comerci / Ugalde
info@caspr.bio
Buenos Aires

CRISPR Platform

1

Table 6.2: AgTech, Food & Reproductive Technologies

Company
Lead Researcher / Founder
Email / Contact Channel
Location / Institutional Link
Bioheuris
Carlos Perez (Strategy)
carlos.perez@bioheuris.com
St. Louis (USA) & Argentina

1100 Corporate Square Dr (USA)

5
Biofeed Tech
Lilia Renée Cavaglieri
contacto@biofeedtech.com.ar
Córdoba

UNRC / CONICET (Implied)

1
Fecundis
Rita Vassena
vassena@fecundis.com

dpo@fecundis.com
Barcelona (Spain) & Rosario

C/ Pamplona 3, Sant Cugat (Spain)

6
Argentag
Leandro Ciappina
hi@argentag.com

welcome@argentag.com
Rosario

CIFASIS (UNR-CONICET)

2
Infira
Renata Reinheimer
Via Empretec / IAL Directory
Santa Fe

IAL (CONICET-UNL)

2
Agro Cultiva
--
Via CONICET Vinculación
Rafaela, Santa Fe

Dairy Basin focus

9
Microgenesis
Gabriela Gutiérrez
Via CONICET Vinculación
Buenos Aires

Female Microbiome

2

Table 6.3: Energy, Industry & Materials

Company
Key Contact
Email / Contact Channel
Location / Institutional Link
Y-TEC
Corporate Affairs
info@ypftecnologia.com
Berisso / La Plata

Av. del Petróleo Argentino s/n

1
La.Te. Andes
--
info@lateandes.com
Salta

Geothermy & Hydrocarbons

9
Hybridon
Galo Soler Illia
ins@unsam.edu.ar

gsoler-illia@unsam.edu.ar
San Martín, BA

INS - UNSAM

19
Nano Soluciones
--
Via PTLC Santa Fe
Santa Fe

Predio Dr. Alberto Cassano

21
Bitgenia
--
info@bitgenia.com
Buenos Aires

Bioinformatics

13
Merel
Elida Beatriz Hermida
ehermida@unsam.edu.ar
San Martín, BA

UNSAM (Regenerative Membrane)

9

7. Strategic Conclusions and Future Outlook
The analysis of the CONICET EBT ecosystem reveals a sector in a state of "accelerated maturation." The days of purely academic spin-offs struggling for survival are transitioning into a new era of professionally managed, globally oriented companies.
1. The "Born-Global" Imperative:
The most successful companies (Bioheuris, Fecundis) have decoupled their R&D location from their Commercial location. By keeping R&D in Argentina, they leverage the country’s high density of doctoral talent and lower operational costs. By establishing headquarters in the USA or Europe, they gain access to trusted regulatory bodies (USDA, FDA, EMA) and deep capital markets. This dual-structure is likely to become the standard blueprint for future Argentine biotech unicorns.
2. Decentralization as a Competitive Advantage:
The emergence of the Santa Fe-Rosario axis is not accidental. It is the result of sustained investment in specific institutes (IAL, CIFASIS, PROIMI). This specialization allows for network effects—AgTech startups in Santa Fe benefit from shared infrastructure and a specialized labor pool that a generic hub in Buenos Aires might not offer.
3. The Rise of the "Platform" Company:
Inmunova and Chemtest demonstrate that the most resilient companies are those built on platform technologies, not single products. The ability to pivot from HUS to COVID-19, or from human to veterinary diagnostics, provides these companies with a hedge against market volatility and regulatory setbacks.
4. Public-Private Operational Fusion:
The Joint Venture models of Y-TEC and La.Te. Andes show that for capital-intensive sectors (Energy, Mining), the state is willing to act as a co-investor and operational partner, not just a licensor. This creates a stability that attracts long-term industrial planning.
In conclusion, the CONICET EBT ecosystem has graduated from an experimental policy initiative to a robust engine of the Argentine knowledge economy. For international investors and industrial partners, the entry points are clear: look for the "Campus Companies" at UNSAM and UNL for deep tech, and the specialized clusters in Rosario and Córdoba for AgTech and genomics. The contact metadata provided in this report serves as the initial roadmap for navigating this high-potential landscape.
Works cited
EMPRESAS DE BASE TECNOLÓGICA CONICET, accessed December 11, 2025, https://www.conicet.gov.ar/wp-content/uploads/EBTs_ESP_PREVIEW.pdf
Las startups que posicionan a Argentina como líder en biotecnología se lucieron en la BioArgentina 2021 | CONICET, accessed December 11, 2025, https://www.conicet.gov.ar/las-startups-que-posicionan-a-argentina-como-lider-en-biotecnologia-se-lucieron-en-la-bioargentina-2021/
Empresas de Base Tecnológica - CONICET – Vinculación, accessed December 11, 2025, https://vinculacion.conicet.gov.ar/empresas-de-base-tecnologica/
XI CAB2C, accessed December 11, 2025, http://2021.a2b2c.org.ar/Book.pdf
CBI Deleted August 4, 2023 Bernadette Juarez APHIS Deputy Administrator Biotechnology Regulatory Services 4700 River Rd, Unit 98, accessed December 11, 2025, https://www.aphis.usda.gov/sites/default/files/23-216-01rsr-submission.pdf
Fecundis Lab, SL - Parc Científic de Barcelona - UB, accessed December 11, 2025, https://www.pcb.ub.edu/en/empresa/fecundis-lab-sl/
XIX Simposio Internacional sobre Enfermedades Desatendidas - Mundo Sano, accessed December 11, 2025, https://www.mundosano.org/wp-content/uploads/2019/08/08-28-Libro-de-res%C3%BAmenes.pdf
Fernando Goldbaum | Fundación Konex, accessed December 11, 2025, https://www.fundacionkonex.org/b4586-fernando-alberto-goldbaum
conicet - start-ups, accessed December 11, 2025, https://www.conicet.gov.ar/wp-content/uploads/START-UPS.pdf
Program - esact, accessed December 11, 2025, https://esact.org/wp-content/uploads/esact_programa_2022.v13.pdf
INM004: Polyclonal Neutralizing Antibodies Against Shiga Toxin as a Treatment for Hemolytic Uremic Syndrome - MDPI, accessed December 11, 2025, https://www.mdpi.com/2072-6651/17/6/282
(PDF) Improving bioreactor production of a recombinant glycoprotein in Escherichia coli: Effect of specific growth rate on protein glycosylation and specific productivity - ResearchGate, accessed December 11, 2025, https://www.researchgate.net/publication/330995856_Improving_bioreactor_production_of_a_recombinant_glycoprotein_in_Escherichia_coli_Effect_of_specific_growth_rate_on_protein_glycosylation_and_specific_productivity
EMPRESAS DE BASE TECNOLÓGICA CONICET, accessed December 11, 2025, https://www.conicet.gov.ar/wp-content/uploads/Empresas-de-Base-Tecnologica-CONICET.pdf
Oncoliq | When cancer is detected early, accessed December 11, 2025, https://www.oncoliq.bio/
Study Details | NCT04906330 | Oncoliq: Test for Early Breast Cancer Detection., accessed December 11, 2025, https://clinicaltrials.gov/study/NCT04906330
CBI Deleted February 2nd, 2023 Bernadette Juarez APHIS Deputy Administrator Biotechnology Regulatory Services 4700 River Rd, Uni, accessed December 11, 2025, https://www.aphis.usda.gov/biotechnology/downloads/confirmation-response/23-033-02cr-request.pdf
Big data e Inteligencia Artificial: cómo subirse a la ola sin ahogarse - Fundación Empretec, accessed December 11, 2025, https://empretec.org.ar/wp-content/uploads/2023/12/Innovacion-n12.pdf
Privacy Policy - Fecundis, accessed December 11, 2025, https://www.fecundis.com/privacy_policy.html
Grupo de investigación - Instituto de Nanosistemas - UNSAM, accessed December 11, 2025, https://www.unsam.edu.ar/institutos/ins/grupo-Soler.php
Nanoarquitecturas - Instituto de Nanosistemas - UNSAM, accessed December 11, 2025, https://www.unsam.edu.ar/institutos/ins/investigacion/SIntesis-y-caracterizacion-de-materiales.php
Physiological and Morphological Responses of Green Microal 2020 Environmenta - Scribd, accessed December 11, 2025, https://www.scribd.com/document/909524811/Physiological-and-Morphological-Responses-of-Green-Microal-2020-Environmenta
Team | ArgenTag 2025, accessed December 11, 2025, https://www.argentag.com/team
Nosotros | Biotalife Skin, accessed December 11, 2025, https://biotalifeskin.com/nosotros/

